Clinical trials: Liver and Intrahepatic Biliary Tract Cancer
Liver Cancer, Colorectal Cancer
The Inflammatory Response to Stress and Angiogenesis in Liver Resection
Patients with resectable liver metastases of colorectal origin will be assigned to laparoscopic liver resection or conventional open liver surgery. Blood samples will be drawn preoperatively and 24 hours after resection.
- Conditions
- Liver Cancer, Colorectal Cancer, Metastatic Cancer, Liver Metastases
- Trial name
- NCT03131778
- Testing
- Liver resection
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ghent
Liver Cancer
Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
This prospective, single-center observational study evaluates the diagnostic accuracy of a novel Folate-targeted Near-Infrared II Carbon Dot (FA-CDots) probe for the ex vivo assessment of Hepatocellular Carcinoma (HCC).
- Trial name
- NCT07295340
- Testing
- Ex Vivo FA-CDots Staining
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma, Liver Cirrhosis
Sonazoid Enhanced Liver Cancer Trial for Early Detection
The aim of this study is to prove usefulness of contrast-enhanced ultrasound (CE-US) using Sonazoid (TM) in the early detection of HCC as compared with conventional B-mode ultrasound (B-mode US) for hepatitis virus related…
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Hepatitis B, Hepatitis C
- Trial name
- NCT00822991
- Testing
- CE-US (Sonazoid™), B-mode US
- Where
- Japan
- Volunteers
- 760 people
- Sponsor
- Kindai University
Intrahepatic Cholangiocarcinoma, Liver Tumor
Treat Primary and Metastatic Liver Tumors
The use of Radiospheres in the management of intrahepatic cholangiocarcinoma is largely unknown and not reported in the medical literature.
- Conditions
- Intrahepatic Cholangiocarcinoma, Liver Tumor, Metastatic Cancer, Metastatic Liver Cancer
- Trial name
- NCT05240040
- Sponsor
- Methodist Health System
Lung Cancer, Liver Cancer
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or…
- Conditions
- Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05187338
- Testing
- ipilimumab +pembrolizumab +durvalumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Gastrointestinal Cancer, Liver Cancer
Collecting Solid Tumor Tissue to Identify New Treatments
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells…
- Conditions
- Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer, Melanoma
- Trial name
- NCT01658917
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Liver Metastases
Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer
Radiation is a standard treatment option for patients with liver cancer. Unfortunately, the tumour grows after radiation in many patients and radiation can harm normal tissues.
- Trial name
- SAVIOR (NCT04745390)
- Testing
- Radiation therapy
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Brain and Central Nervous System Tumors, Kidney Cancer
MT2004-30: Tomotherapy for Solid Tumors
RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation…
- Conditions
- Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma
- Trial name
- NCT00623077
- Testing
- filgrastim, busulfan, etoposide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Liver Cancer
Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01009801
- Testing
- doxorubicin-eluting beads, everolimus
- Where
- 8 sites in Switzerland
- Volunteers
- 27 people
- Sponsor
- Swiss Cancer Institute
Adult Primary Hepatocellular Carcinoma, Recurrent Adult Primary Liver Cancer
TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer
This randomized phase II trial studies how well transarterial chemoembolization (TACE) works compared with TACE plus radiation therapy in treating patients with end stage liver disease, liver tumors, or potential liver transplant…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Recurrent Adult Primary Liver Cancer, Stage I Adult Primary Liver Cancer, Stage II Adult Primary Liver Cancer
- Trial name
- NCT02070419
- Testing
- transarterial chemoembolization, stereotactic radiosurgery
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Hepatocellular Carcinoma
Adjuvant Radiotherapy Comparing TACE for Curative HCC
Despite advances in our understanding of hepatocellular carcinoma (HCC) and its diagnosis, the prognosis for patients with HCC remains disheartening, due to a high recurrence rate and frequent intrahepatic metastasis.
- Trial name
- ARTC-HCC (NCT02125396)
- Testing
- Transarterial chemoembolization, Radiotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangxi Medical University
Liver Cancer
Trajectory-Based Prognostic Modeling in Hepatocellular Carcinoma
To evaluate whether tracking changes in key blood markers over time, together with clinical features, can improve the prediction of outcomes in patients with hepatocellular carcinoma (HCC).
- Trial name
- NCT07204262
- Testing
- Molecular Targeted Therapy (TKI / anti-VEGF antibody) PD-(L)1 Inhibitor Immunotherapy Interventional Therapy (TACE / HAIC)
- Where
- China
- Volunteers
- 379 people
- Sponsor
- Xu Yong, MD
Hepatocellular Carcinoma, Childhood, Fibrolamellar Carcinoma
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
- Conditions
- Hepatocellular Carcinoma, Childhood, Fibrolamellar Carcinoma, Liver Cancer, Liver Cancer, Pediatric
- Trial name
- NCT04134559
- Testing
- Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Allison O'Neill, MD
Hepatocellular Carcinoma
Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)
The purpose of this registry study is to gather effectiveness, QoL, safety and procedural information on TheraSphere® for the treatment of participants with Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (iCC)…
- Trial name
- PROACTIF (NCT04069468)
- Testing
- TheraSphere
- Where
- 37 sites in France
- Volunteers
- 1,247 people
- Sponsor
- Boston Scientific Corporation
Cancer, Advanced Hepatocellular Carcinoma
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients
The main purpose of the study is to establish a safe dose of AZD8055 in patients with mild or moderate liver disease by providing information on any potential side effects this drug may cause and collecting data about how…
- Trial name
- NCT00999882
- Testing
- AZD8055
- Where
- 3 sites in Hong Kong, South Korea
- Volunteers
- 26 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC
The aim of this study is to collect data on efficacy and tolerability on a large series of patient of different Italian hospitals in order to support the validation of LifePearl with robust and consistent clinical evidence.
- Trial name
- LIFDOX (NCT03734068)
- Testing
- Chemoembolization Using LifePearl, Doxorubicin
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- International Group of Endovascular Oncology
Hepatocellular Carcinoma, Cirrhosis
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy.
- Trial name
- NCT06007846
- Testing
- Namenda
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Inova Health Care Services
Lung Cancer, Gastric Cancer
INSPIRE: a Multi-Cancer Early Detection Study
This research constitutes a multi-centric, case-control designed investigation aimed at developing and implementing a blinded validation of a machine learning-powered, multi-cancer early detection model.
- Conditions
- Lung Cancer, Gastric Cancer, Liver Cancer, Colorectal Cancer
- Trial name
- INSPIRE (NCT06440018)
- Where
- China
- Volunteers
- 5,350 people
- Sponsor
- Singlera Genomics Inc.
Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
This phase II trial studies how well selumetinib and Akt inhibitor MK-2206 work in treating patients with refractory or advanced gallbladder or bile duct cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
- Trial name
- NCT01859182
- Testing
- selumetinib, Akt inhibitor MK2206, laboratory biomarker analysis
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.